tiprankstipranks
Adaptimmune initiated with a Buy at EF Hutton
The Fly

Adaptimmune initiated with a Buy at EF Hutton

EF Hutton analyst Tony Butler initiated coverage of Adaptimmune with a Buy rating and $10 price target. Adaptimmune is a cell therapy company whose pipeline is centered on its comprehensive T-cell therapeutic platform, Butler tells investors in a research note. The analyst sees a high probability of the approval of the Biologics License Application for afami-cel to treat synovial sarcoma.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on ADAP:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles